| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2020 , Vol 58 , Num 2
Dose-dependent Efficacy of the N-acetylglucosamine and Quercetin Combination in Rats with Renal Failure
1 Department of Clinical Pharmacology & Clinical Pharmacy, National University of Pharmacy, 27 Pushkinska Str., Kharkiv, Ukraine, 610572 Department of General Practice ? Family Medicine, School of Medicine, V. N. Karazin Kharkiv National University, 4 Svobody Sq., Kharkiv, Ukraine, 61022
DOI : 10.23893/1307-2080.APS.05809 Viewed : 18122 - Downloaded : 5908 The study was devoted to the evaluation of dose-dependent efficacy of N-acetylglucosamine and quercetin combination in the treatment of renal failure. The combination was studied in injectable dosage form at the doses of 10, 20, 40 and 60 mg/kg in rats with chromium-induced nephropathy. The efficacy of combination was assessed by animal survival, renal excretory function, nitrogen metabolism and nephroprotective activity. Also, the ED50 index was calculated by Probit Analysis method. The efficacy of combination at doses of 40 and 60 mg/kg was most expressed with insignificant differences (p>0.05) between them. There was a significance increase (p<0.05) in animal survival, renal excretory function and normalization of nitrogen metabolism. This led to the nephroprotective activity of 67.8 and 70.4%, respectively. The ED50 index of combination was 30.2 ± 6.3 mg/ kg. Thus, this test combination at a dose of 30.2 mg/kg is the promising drug for experimental treatment of kidney diseases. Keywords : N-acetylglucosamine, Quercetin, Nephroprotective effect, Median effective dose, Renal failure